Skip to main content

Ophthalmology

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.

We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes novel therapeutic modalities such as gene therapies, cell-based therapies and potential treatments for geographic atrophy (GA).

Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to preserve and restore vision.

Partnering opportunities we are looking for:

  • Retinal diseases and long-acting ocular drug delivery solutions

  • Glaucoma and dry eye disease

Example partnerships

  • AntlerA

    Acquisition of Wnt targeting programs for potential best-in-class treatment for multiple indications including neovascular age-related macular degeneration and diabetic macular edema

  • ForSight VISION4

    Acquisition to acquire Susvimo™ for long-acting ocular delivery

  • Lineage Cell Therapeutics

    Collaboration and license agreement for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).

  • SemaThera

    Research collaboration targeting SEMA3A for diabetic retinopathy (DR)

Explore collaboration opportunities

Connect with our partnering experts to start the conversation.

Reach out

More Pharma partnering areas

View all areas
Decorative illustration

Digital and data

Innovation

We are taking PHC toward a future where treatments are targeted to an individual’s needs and unique genetic profile.

Decorative illustration

Immunology

Innovation

Leading the way to advance science in inflammatory and autoimmune diseases.

Decorative illustration

Infectious Diseases

Innovation

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR.

Decorative illustration

Neurology

Innovation

We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders.

Decorative image

Oncology and Haematology

Innovation

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy.

Decorative illustration

Research Technologies

Innovation

We focus on therapeutic modalities and enabling technologies.

Decorative illustration

Cardiovascular, Renal & Metabolic Disease

Innovation

Roche is committed to making a contribution to areas of huge unmet need and societal burden through transformative science like in cardiovascular and metabolic diseases

References 

  1. Word Health Organization. Blindness and vision impairment. [Internet; cited April 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment

Discover more

  • Ophthalmology

    Pharma

    We are focused on pioneering therapies to prevent vision loss, working to discover and develop innovative solutions, aiming to redefine standards of care for people living with of vision impairment.

  • Neurology

    Pharma | Diagnostics

    We're pushing boundaries of scientific understanding to achieve clinical advancements and solve some of the greatest challenges in neurology today.

  • Rare disease

    Pharma | Diagnostics

    Working together to build a better world for people with rare diseases.

  • Product Development Pipeline

    Solutions

    Discover our pipeline of Pharmaceutical and Diagnostics developments